HB2097 amends Virginia law to require coverage for prostate cancer screening in several categories of health coverage, including state employee health plans, Medicaid, and individual and group health insurance policies. The bill specifically adds or updates coverage for PSA testing and digital rectal examinations for men age 50 and older, and for men age 40 and older who are at high risk for prostate cancer under American Cancer Society guidelines. It also clarifies that the coverage applies to policies, contracts, and plans delivered, issued for delivery, or renewed in Virginia on or after January 1, 2026.
Beyond the prostate cancer screening provisions, the bill largely reenacts and updates existing mandated-benefit language in the state employee plan and Medicaid statutes, preserving a broad set of required benefits and administrative rules. These include coverage for mammograms, pap smears, postpartum care, early intervention services, contraceptives, cancer drugs, diabetes education, breast reconstructive surgery, colorectal cancer screening, infant hearing screenings, telemedicine-related services, and other mandated benefits already embedded in the Code of Virginia. The bill also makes conforming changes to the small-employer insurance section so that prostate cancer screening remains one of the few state-mandated benefits that small-group plans must include.
The bill’s practical impact is to expand and standardize prostate cancer screening coverage across major insurance markets in Virginia, while leaving the broader structure of mandated health benefits intact. It affects state employee coverage, Medicaid coverage, and private insurers offering individual, group, and small-employer plans, and it may increase utilization of preventive screening services. The bill also preserves existing cost-sharing rules, including the exception for high-deductible health plans tied to health savings accounts.
The overall sentiment around the bill was strongly favorable and noncontroversial. It advanced unanimously at every recorded stage, including subcommittee, full committee, House passage, Senate committee, and final Senate passage, with no recorded dissenting votes. The vote history suggests broad bipartisan support and little opposition to the screening mandate.
The main point of contention, to the extent one can be identified from the text, is the scope of mandated coverage and the associated cost implications for insurers and public plans. However, no specific objections appear in the available transcripts or votes. The bill’s structure also reflects a policy balance between expanding preventive care and preserving existing exceptions for certain limited policies and high-deductible health plans.
HB2097 amends sections of the Code of Virginia governing state employee health insurance, Medicaid, and private health insurance mandates. The most direct legal change is the addition and clarification of prostate cancer screening coverage requirements, including PSA testing and digital rectal exams, in state employee plans, Medicaid, and individual/group insurance policies. It also updates the small-employer mandate statute so prostate cancer screening remains a required benefit in that market, while other state-mandated benefits generally remain optional for small employers unless otherwise required by law.
The bill appears to have been received positively throughout the legislative process. It passed subcommittee, committee, the House, and the Senate unanimously, with recorded votes of 7-0, 22-0, 97-0, 15-0, 39-0, and 40-0. No committee transcript objections are available, and the unanimous votes indicate broad support and little visible controversy.
No major contention is evident in the available record. The only likely policy issue is the cost and administrative effect of requiring additional preventive coverage across multiple insurance markets and public plans, especially for insurers and state-funded programs. The bill also preserves exceptions for certain limited policies and high-deductible health plans, which suggests an effort to avoid conflict with existing insurance structures and federal HSA rules.